281 related articles for article (PubMed ID: 26278713)
1. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
2. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
3. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
4. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
[TBL] [Abstract][Full Text] [Related]
5. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
6. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in gastric cancer and future perspectives.
Yazici O; Sendur MA; Ozdemir N; Aksoy S
World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
14. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
15. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in esophageal cancer.
Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
[TBL] [Abstract][Full Text] [Related]
17. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
18. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P
Oncology; 2015; 89(1):1-13. PubMed ID: 25720422
[TBL] [Abstract][Full Text] [Related]
19. The role of targeted therapy for gastrointestinal tumors.
Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the treatment of gastrointestinal stromal tumour.
Kasireddy V; von Mehren M
Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]